Nanoviricides (NNVC) Change in Accured Expenses (2010 - 2026)
Nanoviricides (NNVC) posted Change in Accured Expenses of -$15792.0 for Q1 2026, down 202.96% sequentially from $15338.0 in Q4 2025, and down 297.78% YoY from $7984.5 in Q1 2025.
Nanoviricides (NNVC) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Nanoviricides has reported Change in Accured Expenses for 17 years, with the latest figure at -$15792.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 297.78% year-over-year to -$15792.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6770.0 (up 97.01% YoY) and the FY2025 annual result came in at -$236498.0, down 240.34% from the prior year.
- Change in Accured Expenses eased to -$15792.0 in Q1 2026 per NNVC's latest filing, from $15338.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $195863.0 in Q3 2023 and troughed at -$246706.0 in Q4 2024.
- A 5-year average of $3029.3 and a median of $1095.0 in 2022 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 34544.07% in 2022, down 10366.67% in 2022.
- Over 5 years, Change in Accured Expenses stood at $28165.0 in 2022, then plunged by 488.58% to -$109443.0 in 2023, then sank by 125.42% to -$246706.0 in 2024, then jumped by 106.22% to $15338.0 in 2025, then sank by 202.96% to -$15792.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$15792.0, $15338.0, and $331.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -15,792.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,792.00 |
| Mar 31, 2026 | -15,792.00 |
| Dec 31, 2025 | 15,338.00 |
| Dec 31, 2025 | 15,338.00 |
| Sep 30, 2025 | 331.00 |
| Sep 30, 2025 | 331.00 |
| Jun 30, 2025 | -6,647.00 |
| Jun 30, 2025 | -6,647.00 |
| Mar 31, 2025 | -3,970.00 |
| Mar 31, 2025 | -3,970.00 |
| Dec 31, 2024 | -246,706.00 |
| Dec 31, 2024 | -246,706.00 |
| Sep 30, 2024 | 20,825.00 |
| Sep 30, 2024 | 20,825.00 |
| Jun 30, 2024 | 3,673.00 |
| Jun 30, 2024 | 3,673.00 |
| Mar 31, 2024 | 78,423.00 |
| Mar 31, 2024 | 78,423.00 |
| Dec 31, 2023 | -109,443.00 |
| Dec 31, 2023 | -109,443.00 |